2μg (R: reducing condition, N:non-reducing condition).
Product Details
Product Details
Product Specification
| Species | Human |
| Synonyms | CD8, Leu2, MAL, p32 |
| Accession | P01732-1 |
| Amino Acid Sequence | Ser22-Asp182 with His&Avi Tag at the C-Terminus |
| Expression System | HEK293 |
| Molecular Weight | 25-35kDa (Reducing) |
| Purity | >90% by SDS-PAGE |
| Conjugation | Biotin |
| Tag | Avi Tag, His Tag |
| Physical Appearance | Lyophilized powder |
| Storage Buffer | PBS, pH7.4, 5% trehalose |
| Reconstitution | Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation. |
| Stability & Storage |
· 12 months from date of receipt, lyophilized powder stored at -20 to -80℃. · 3 months, -20 to -80℃ under sterile conditions after reconstitution. · 1 week, 2 to 8℃ under sterile conditions after reconstitution. · Please avoid repeated freeze-thaw cycles. |
| Reference | 1. Andreata F, Moynihan K D, Fumagalli V, et al. CD8 cis-targeted IL-2 drives potent antiviral activity against hepatitis B virus[J]. Science Translational Medicine, 2024, 16(729): eadi1572. |
Background
CD8α (the CD8 alpha chain, encoded by CD8A) is the α chain of the CD8 co-receptor, a type I transmembrane glycoprotein of the immunoglobulin superfamily composed of an extracellular Ig-like V domain, hinge and transmembrane regions, and a short cytoplasmic tail. It assembles with CD8β into the CD8αβ heterodimer or as the CD8αα homodimer. As a co-receptor for the T-cell receptor (TCR), CD8α binds MHC class I molecules and recruits Lck, thereby increasing antigen-recognition sensitivity and lowering the activation threshold of cytotoxic T cells; its expression also modulates TCR specificity and avidity. Clinically, CD8α/CD8 has become an attractive target: CD8 cis-targeted IL-2 selectively reactivates dysfunctional CD8⁺ T cells against chronic hepatitis B; CD8-targeted DARPin-AAV enables in vivo T-cell gene delivery and CAR engineering; CD8-targeted nanobody PET tracers such as SNA006 non-invasively monitor tumour CD8⁺ T-cell infiltration and immunotherapy response; and CD8α hinge/transmembrane domains improve CAR-T affinity and antitumour efficacy.
Picture
Picture
SDS-PAGE
ELISA
Immobilized Mouse Anti-Human CD8α Antibody (OKT-8) (Cat. No. S0B8453) at 1 μg/mL (100 μL/well) can bind Biotinylated CD8 alpha/CD8A His&Avi Tag Protein, Human (Cat. No. UA016229) with a linear range of 5.1-8.7 ng/mL.
Immobilized Biotinylated CD8 alpha/CD8A His&Avi Tag Protein, Human (Cat. No. UA016229) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate. can bind Mouse Anti-Human CD8α Antibody (OKT-8) (Cat. No. S0B8453) with a linear range of 0.32-0.44 ng/mL.
